

## **Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK Biobank**

CM Schooling, JV Zhao, SL Au Yeung, GM Leung

Corresponding Author: CM Schooling, PhD.  
1/F, Patrick Manson Building (North Wing), 7 Sassoon Road, Pokfulam, Hong Kong  
Tel: 852 3917 6732 Email: cms1@hku.hk

CM Schooling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, USA

JV Zhao, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

SL Au Yeung, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

GM Leung, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China,

### **Section 1: What is already known on this topic**

Statins appear to have pleiotropic effects on cardiovascular disease. Whether such effects exist and why they should occur is unclear, but could be highly relevant to the prevention and treatment of the leading cause of death.

### **Section 2: What this study adds**

Our study shows that statins have similar protective effects on ischemic heart disease via low-density lipoprotein cholesterol in men and women, but unlike other major lipid modifiers statins have an additional effect specific to men via testosterone, while any harms of anakinra in men may operate by a similar mechanism. Our findings highlighting the possibility of sex-specific causes of cardiovascular disease and the need for sex-specific investigations, prevention and treatment.

## **Abstract**

**Objectives:** Statins appear to have pleiotropic effects. We examined whether specifically statins, of the major lipid modifiers, operate on ischemic heart disease (IHD) via testosterone. As a validation, we assessed whether a drug that unexpectedly likely increases IHD also operates via testosterone.

**Design:** A sex-specific univariable and multivariable Mendelian randomization study

**Setting:** A large, population-based cohort study recruited in the UK from 2006-10, the UK Biobank

**Participants:** 179918 men with 25410 IHD cases and 212080 women with 12511 IHD cases

**Main Outcome measures:** Testosterone and IHD

**Results:** Of the three lipid modulations considered, statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe, only genetically predicted statin use in men affected testosterone (-0.15 effect size testosterone per effect size lower (of low-density lipoprotein cholesterol), 95% confidence interval (CI) -0.23 to -0.06). The genetically predicted effect of statin use on IHD in specifically men was partially mediated by testosterone (odds ratio (OR) 0.55 per effect size lower (low-density lipoprotein cholesterol), 95% CI 0.38 to 0.79, compared to OR 0.73, 95% CI 0.46 to 1.11 after allowing for testosterone). The estimate for the effect of genetically predicted statin use, independent of testosterone, was very similar in women, giving overall meta-analyzed OR 0.72, 95% CI 0.57 to 0.90 per effect size lower of low-density lipoprotein cholesterol. The genetically predicted effect of anakinra use also affected testosterone (0.022 per effect size (of IL-1 Ra), 95% CI 0.01 to 0.04), and increased IHD in men.

**Conclusions:** Statins may partially operate via testosterone in men, which may contribute to sex-specific pleiotropic effects. Anakinra operating by testosterone may also explain its unexpected effects. Our findings could facilitate the development of new interventions for cardiovascular diseases as well as highlighting the importance of sex-specific investigations and possibly treatments.

Abstract: 289

Words: 3572

## Background

Statins are the first-line lipid modifier for reducing cardiovascular morbidity and mortality [1, 2]. Statins have revolutionized the prevention and treatment of cardiovascular disease, and inspired the development of a range of effective interventions targeting the reduction of low-density lipoprotein (LDL)-cholesterol. Statins have long been suspected of having additional beneficial effects beyond lipid modulation [3], such as on inflammation [3], another potential target for reducing cardiovascular disease [4]. Meta-analysis of randomized controlled trials (RCTs) suggests statins are more effective at reducing mortality than proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or ezetimibe [5, 6]. However, these findings may be more apparent than real, stemming from differences in trial design, such as shorter duration of the PCSK9 inhibitor trials [6], the predominance of industry funded statin trials [7] or the difficulty of interpreting trials of “soft” events when the treatment affects diagnostically relevant criteria, i.e., lipid levels [8]. To investigate this anomaly, a previous study conducted a systematic agnostic scan of metabolic profile in a trial of statins compared to a PCSK9 inhibitor, which found few differences [9]. While characterization of the metabolic effects of statins suggested extensive effects on lipids and fatty acids [10]; these investigations were not able to include a factor which has previously been proposed as contributing to statin’s effectiveness, i.e., effects on male hormones [11], although questions have been raised as to whether statins are as effective in women as men [12]. However, meta-analysis of the available trial evidence suggests similar relative benefits of LDL-cholesterol reduction by statins for men and women [13], although the trials mainly concern men (73.2%) which may preclude detection of important sex differences. Men are also at substantially higher risk than women [14] giving larger absolute benefits in men than women at the same reduction in relative risk.

RCTs are not usually designed or powered to test mediating mechanisms. In addition, trials of statins on cardiovascular disease outcomes designed to be sex-specific are lacking. To assess a potential

pathway by which statins might additionally operate, we used Mendelian randomization (MR), an observational study design that avoids confounding by taking advantage of the random allocation of genetic material at conception [15], here specifically the genetic variants corresponding to effects of use of lipid modifiers. This random allocation at conception also avoids selection bias as long as few deaths have occurred between randomization and recruitment due to exposure, outcome, or other causes, i.e., competing risk, of the outcome [16, 17]. So, here we focused on ischemic heart disease (IHD) [18], using the UK Biobank [19] to investigate whether testosterone mediated any of the effects of statins, PCSK9 inhibitors or ezetimibe on IHD in men or women using univariable and multivariable MR. As a further test, given some anti-inflammatories have also been shown to have the opposite effects on male hormones compared to statins, specifically the interleukin 1 receptor antagonist (IL-1Ra), anakinra [20], we assessed whether the genetic variants corresponding to effects of anakinra or tocilizumab use targeting interleukin 6 (IL-6 and IL-6R) had the mirror image pattern of effects on testosterone and IHD [4, 21, 22] to statins. Figure 1 illustrates the possible additional effects of statins, anakinra or tocilizumab on IHD via male hormones in the context of the well-established benefits of statins, PCSK9 inhibitors and ezetimibe acting via LDL-cholesterol and of anti-inflammatories in IHD.

## **Methods**

### **Genetic predictors of effects of lipid and interleukin modifier use**

Established genetic variants corresponding to effects of statin, PCSK9 inhibitor and ezetimibe use were taken from published sources [23] which selected single nucleotide polymorphisms (SNPs) from genes encoding proteins of the targets of each lipid modifier (*HMGCR* for statins, *PCSK9* for PCSK9 inhibitors and *NCP1L1* for ezetimibe) that lowered LDL-cholesterol. Genetic effects of using statins, PCSK9 inhibitors and ezetimibe were expressed in sex-specific effect sizes of LDL-

cholesterol reduction taken from the largest available GWAS summary statistics, i.e., the UK Biobank (<http://www.nealelab.is/uk-biobank>). The study was restricted to people of white British ancestry adjusted for the first 20 principal components, age, and age<sup>2</sup>. For each lipid modifier, we used independent ( $r^2 < 0.05$ ) SNPs most strongly associated with LDL-cholesterol, based on the 1000 Genomes catalog obtained from LDlink (<https://ldlink.nci.nih.gov>) in the main analysis, and then included all relevant SNPs in a sensitivity analysis, accounting for their correlations obtained from LDlink. Established genetic variants corresponding to anakinra and tocilizumab use and their effects on IL-1Ra and IL-6 respectively were also taken from published sources [21, 22].

### **Sex-specific genetic predictors of testosterone**

Strong ( $p\text{-value} < 5 \times 10^{-8}$ ), independent ( $r^2 < 0.05$ ), sex-specific genetic predictors of testosterone were extracted from a published genome wide association study (GWAS) based on the UK Biobank and replicated in three independent studies (CHARGE Consortium, Twins UK and EPIC-Norfolk) [24, 25]. Genetic associations with testosterone in this study were adjusted for genotyping chip/release of genetic data, age at baseline, fasting time and ten genetically derived principal components [24]. We used all 125 genetic variants given for bioavailable testosterone, hereafter testosterone, in men and all 254 genetic variants given for testosterone in women, as previously [26], because these had little correlation with sex hormone binding globulin (0.05 in men and 0.06 in women) [24].

### **Sex-specific genetic associations with IHD**

Sex-specific genetic associations with IHD were taken from the UK Biobank individual data after excluding those with inconsistent self-reported and genotyped sex, excess relatedness (more than 10 putative third-degree relatives), abnormal sex chromosomes (such as XXY), or poor-quality genotyping (heterozygosity or missing rate  $> 1.5\%$ ). The sex-specific association with IHD were adjusted for the first 20 principal components, age, and assay array. IHD was based on self-report at

baseline, subsequent health service encounter diagnoses (primary or secondary) of International Classification of Diseases (ICD) 9 410-4 or ICD10 I20-5 and death registration causes (primary or secondary) of ICD10 I20-5 up until December 2019.

### **Statistical analysis**

The F-statistic was used to assess instrument strength, obtained using an approximation (mean of square of SNP-exposure association divided by square of its standard error) [27]. A conventional threshold for the F-statistic is 10. SNPs with an F-statistic <10 were dropped.

Sex-specific estimates of the associations of genetically predicted exposures (i.e., genetically predicted effects of statin, PCSK9 inhibitor, ezetimibe, anakinra and tocilizumab use) with testosterone and IHD, as well as estimates of the associations of genetically predicted testosterone with IHD were obtained by combining SNP-specific Wald estimates (SNP on outcome divided by SNP on exposure) using inverse variance weighting (IVW) with multiplicative random effects [28]. Multivariable MR was used to assess sex-specific associations of genetically predicted exposures with IHD allowing for testosterone, accounting for correlations between SNPs on the same chromosome obtained from LDlink. In the multivariable MR, we estimated the Sanderson-Windmeijer conditional F-statistic [29] to obtain a lower bound of the strength for each instrument conditional on the other exposure, and the Q statistics to assess pleiotropy, using the WSpiller/MVMR package [30].

### **Sensitivity analysis**

Where possible we used methods with different assumptions to assess the validity of the MR estimates from IVW, which assumes balanced pleiotropy. MR-Egger is valid as long as the instrument strength independent of direct effect assumption holds [31]. We also used a weighted

median which gives valid estimates when more than 50% of information comes from valid SNPs [32]. However, for exposures instrumented by correlated SNPs we did not give the weighted median or MR-Egger estimates because of concerns about their interpretability [33].

All statistical analysis was conducted using R version 3.6.1 (The R Foundation for Statistical Computing, Vienna, Austria). The MendelianRandomization R package was used for the MR estimates. Estimates of genetic associations were taken from publicly available UK Biobank summary statistics, except the associations with IHD which were based on individual level genetic associations from the UK Biobank obtained under application #42468. All UK Biobank data was collected with fully informed consent.

### **Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

### **Results**

The six SNPs for the effects of statin use (rs12916, rs5909, rs10066707, rs17238484, rs2006760 and rs2303152) [23] were all correlated ( $r^2 > 0.13$ ). In the main analysis we used only the lead SNP, rs12916. Of the 7 SNPs for the effects of PCSK9 inhibitor use (rs11206510, rs2149041, rs7552841, rs10888897, rs2479394, rs2479409 and rs562556) [23], the three independently ( $r^2 < 0.05$ ) and most strongly associated with LDL-cholesterol (rs11206510, rs2149041 and rs7552841) were used in the main analysis. Of the 5 SNPs for the effects of ezetimibe use (rs10260606 (proxy of rs2073547), rs2300414, rs10234070, rs7791240, rs217386) [23], two SNPs (rs2300414 and rs10234070) were discarded because their F-statistic for LDL-cholesterol was  $< 10$ . The remaining three SNPs were all correlated at  $r^2 > 0.05$ . rs2073547 was used in the main analysis because it had

the strongest association with LDL-cholesterol. Table S1 shows the associations with LDL-cholesterol by sex for the independent SNPs used to predict effects of statin, PCSK9 inhibitor and ezetimibe use. Table S2 shows the associations of the two SNPs for the effects of the use of the anti-inflammatory, anakinra, (rs6743376 and rs1542176 ( $r^2 < 0.001$ )) with IL-1Ra and the associations of the SNP (rs7529229), used to predict effects of tocilizumab use, with IL-6.

There were 179,918 men with 25,410 cases of IHD and 212,080 women with 12,511 cases of IHD in the UK Biobank.

### **Instrument strength**

The F-statistics for SNPs used to genetically predict the effects of statin, PCSK9 and ezetimibe use were all  $>10$  in men and women (Table S1), as were the F-statistics for the SNPs used to genetically predict the effects of anakinra and tocilizumab use (Table S2). The F-statistics for the 125 and 254 SNPs predicting testosterone in men and women were all greater than 10, with mean 128.6 and 83.3, respectively (Tables S3 and S4).

### **Sex-specific associations of genetically predicted lipid modifiers with testosterone**

Genetically predicted effects of statin use reduced testosterone in men but not women (Table 1). Genetically predicted effects of PCSK9 inhibitors or of ezetimibe did not affect testosterone in men or women (Table 1). Findings were similar in sensitivity analysis using a larger number of SNPs, where available (Table 1). PCSK9 inhibitors and ezetimibe were not investigated further, given the lack of association with testosterone in men and women.

### **Sex-specific associations of genetically predicted statin use and testosterone with IHD**

Genetically predicted effects of statin use reduced both testosterone and the risk of IHD in men and possibly women (Table 2) using IVW. Genetically predicted testosterone was positively associated with IHD in men, but less clearly in women, with similar estimates using IVW, the weighted median and MR-Egger. MR-Egger intercepts did not suggest the IVW estimates were invalid, but had wider confidence intervals (Table 2)

Considering genetically predicted effects of statin use together with genetically predicted testosterone, the conditional F-statistics were 58.2 (men) and 68.5 (women) for testosterone and 3.5 (men) and 6.8 (women) for effects of statin use. The Q statistics for instrument validity were significant (212.5 in men and 323.1 in women). Correspondingly, the multivariable MR-Egger intercept was significant in men and women, so we used the MR-Egger estimates. Multivariable associations of genetically predicted testosterone with IHD, adjusted for statin use, (Table 3) were similar to the univariable estimates for men and women (Table 2), but differed by sex (z-test p-value 0.01). For men the multivariable estimate for genetically predicted effects of statin use allowing for testosterone was attenuated (Table 3) compared to the univariable estimates (Table 2). As a result, the estimates for genetically predicted effects of statin use independent of testosterone were very similar for men and women (meta-analyzed odds ratio 0.72, 95% confidence interval 0.57 to 0.90).

### **Sex-specific associations of genetically predicted anakinra and tocilizumab use with testosterone and IHD**

Genetically predicted effects of anakinra use increased both the risk of IHD and testosterone in men but not women (Table 4). Genetically predicted effects of tocilizumab use were not clearly associated with testosterone in men or women (Table 4), so were not investigated further. Investigation of whether testosterone mediates the effect of anakinra use on IHD was not possible

because sex-specific genetic associations of testosterone SNPs with IL-1Ra from suitably large GWAS are not available.

## **Discussion**

Consistent with meta-analysis of RCTs this study provides genetic evidence that statins reduce testosterone in men [11], and adds by showing that statins partially operate on IHD in men only by reducing testosterone, as previously hypothesized [11, 34], while having similar protective effects in men and women independent of testosterone. Previous Mendelian randomization studies have shown lower testosterone associated with lower risk of IHD, particularly in men [35-37]. Conversely, consistent with an RCT [20], this study also provides genetic validation that the anti-inflammatory anakinra, targeting IL-1Ra, increases testosterone in men, and is consistent with a previous Mendelian randomization study showing anakinra increases IHD [22], but adds by showing why these associations might occur and that they may be specific to men.

A more marked association of testosterone with IHD in men than women (Table 2) is consistent with sex differences in biology, where testosterone is the main sex hormone in men and is much higher in men than in women. The associations of genetically predicted effects of statin, PCSK9 inhibitor or ezetimibe use on testosterone is consistent with the evidence available [11, 38, 39] and their mechanisms of action. Specifically, statins inhibit cholesterol synthesis, while PCSK9 inhibitors enable greater clearance of cholesterol, through increasing LDL-receptors, while ezetimibe reduces uptake of dietary cholesterol [1, 2]. However, some cells, such as Leydig cells, use *de novo* cholesterol synthesis to generate steroids, which can be reduced by statins [40]. Concerns about statins compromising androgen production pre-date the marketing of statins [41, 42]. Beneficial immunosuppressive effects of androgens in rheumatoid arthritis have long been known [43],

making androgen reduction a plausible mode of action for therapies, such as anakinra, whose primary indication is rheumatoid arthritis.

These findings may seem counter-intuitive given the essential role of testosterone in masculinity and reproduction. However, in 2015 the Food and Drug Administration in the United States required labelling changes for all testosterone prescriptions to warn of the risk of heart attacks and stroke on testosterone, although no sufficiently large RCT of testosterone administration has been conducted to confirm these effects [44]. The Endocrine Society has also recommended caution in the use of testosterone [45]. Meta-analysis of RCTs suggests androgen deprivation therapy reduces all-cause mortality, but is too small to quantify effects on specific diseases beyond prostate cancer [46]. As such, our Mendelian randomization findings of the effects of testosterone have some consistency with the limited experimental evidence. In addition, our findings are consistent with well-established evolutionary biology theory, i.e. the Darwinian imperative of reproductive success even at the expense of longevity, possibly in a sex-specific manner, implies that central drivers of the reproductive axis, as well as androgen production and catabolism, and their environmental cues may be relevant to IHD [47, 48] (Figure 2) encompassing the relations tested here (Figure 1). Notably, upregulation of indicators of plentiful living conditions, such as insulin, appear to cause IHD, particularly in men [49], likely via gonadotropin releasing hormone (GnRH) [48]. Similarly, fatty acids may affect GnRH [50, 51]. In contrast, indicators of adversity, such as endotoxins promote an inflammatory response, involving interleukins, which suppresses the reproductive axis [52] and thereby testosterone [53], which may be reversed by anakinra possibly outweighing the benefits for IHD of suppressing inflammation [54]. Statins, in contrast reduce androgen production, while agents that suppress androgen catabolism, such as rofecoxib, have also had unexpectedly adverse effects on IHD [47]. Mechanisms by which androgens might cause IHD have not been extensively investigated, but likely involve coagulation and red blood cell attributes. Several haemostatic and thrombotic

factors, such as thromboxane A<sub>2</sub> [55, 56], endothelin-1 [57-59], nitric oxide [55, 60] and possibly thrombin [61, 62], may be driven by androgens and likely play a role in IHD [63-65]. Von Willebrand factor [66] and asymmetric dimethylarginine [67] are also modulated by statins and may cause IHD [4, 68], whether they are driven by testosterone is unknown. Several red blood cell attributes are affected by androgens, from reticulocytes to hematocrit [69, 70], but exactly which causes IHD is unclear, although reticulocytes are a possibility [71]. Currently, comprehensive genetic validation of these pathways is hampered by the lack of availability of large sex-specific GWAS of cytokines and coagulation factors.

Despite providing information that may be relevant to the performance of statins, and to the development of other therapies to protect against cardiovascular disease [72], some limitations of this study exist. First, valid instruments should fulfill three assumptions, i.e., relate strongly to the exposure, not be associated with potential confounders and satisfy the exclusion restriction assumption. The F-statistics were >10. Despite high conditional F-statistics for testosterone the conditional F-statistics for the effects of statin use were quite low and the Q-statistics for instrument validity were high suggesting pleiotropy, which we addressed by using multivariable MR-Egger. The associations with testosterone in women were not adjusted for factors, such as menopausal status, hormone use and history of oophorectomy, which could result in imprecision and weaker instruments. The SNPs used to predict effects of statin, PCSK9 inhibitors and ezetimibe use are well established [23], and in genes that harbor the target of each lipid modifier (*HMGCR*, *PCSK9* and *NCP1L1* respectively). Similarly, the SNPs predicting effects of the anti-inflammatory anakinra use have been validated as increasing IL-1Ra [22], and the SNP used to predict effects of tocilizumab use is well-established as affecting IL-6 and IL-6R [21]. Sex-specific genetic associations were used throughout with exception of the genetic prediction of effects of anakinra and tocilizumab use on IL1Ra and IL-6 respectively. However, inflammation operating on the reproductive axis would be

expected to have sex-specific effects not sex-specific drivers. We selected between correlated SNPs based on p-values which is relatively arbitrary, and the estimates could be sensitive to the choice of SNPs. Repeating the analysis using a larger number of correlated SNPs, where possible, taking into account their correlation, gave a similar interpretation. MR studies can be confounded by population stratification. However, we used genetic associations from GWAS mainly comprising people of white British ancestry with genomic control. Functions of each SNP predicting the exposures are not all fully understood, so we cannot rule out the possibility that the SNPs are linked with IHD through other pathways although we used sensitivity analysis.

We used SNPs predicting testosterone, but not other exposures, obtained from the same study as the genetic effects on IHD. However given the estimates for testosterone were largely obtained from non-cases, the overlap unlikely introduced substantial bias [73]. Canalization, i.e., buffering of genetic factors during development, may occur however; whether it does so is unknown. Our findings, largely in Europeans, may not be applicable to other populations. However, causes are unlikely to act differently in different populations, although the causal mechanisms may not be as relevant in all settings [74]. The SNPs for effects of statin, PCSK9 inhibitors and ezetimibe use were selected for their relations with LDL-cholesterol and on functional grounds, assuming the lipid modifiers act by action on lipids, so it is possible that relevant SNPs might have been discarded if they work through other mechanisms independent of lipids. It is also possible that the SNPs for lipid modifiers might act via a different lipid trait, such as apoB [75]. The SNPs for effects of anakinra and tocilizumab use were similarly selected. Replication based on genetic instruments functionally relevant to all the exposures would be ideal. However, we used the most recent, published genetic instruments for testosterone [24]. Replication based on another large IHD GWAS, such as CARDIoGRAM [65], would be ideal, but it is less intensively genotyped than the UK Biobank and excludes the X chromosome, making it unsuitable. Lastly, Mendelian randomization assesses the

lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT, nevertheless our estimates for statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes [13].

Taken together these complimentary findings for statins and anakinra raise the possibility that modulating testosterone, by whatever means, is a relevant feature for modulating IHD in men, with potential relevance to the development of new interventions, side-effects of existing interventions, re-purposing and appropriate use. Statins lowering testosterone could also be relevant to the muscle weakness or pain experienced on statins [76]. Recognition that statins lower testosterone might also provide greater impetus for investigation of their role in other relevant conditions, such as prostate cancer [77]. Conversely, statins and anakinra did not clearly affect testosterone in women (Table 1) nor did testosterone mediate the effect of statins on IHD in women (Table 3). These differences by sex highlight the need for sex-specific approaches to IHD prevention and management, specifically in terms of the use of statins and investigation more broadly of causes of IHD.

## **Conclusion**

Genetic variants corresponding to the effects of statins and anakinra use had opposite effects on testosterone and IHD in men, consistent with the effects of statins on IHD in men being partially mediated by testosterone. This insight that the pleiotropic effects of statins could be mediated by testosterone in men has implications for the use of existing interventions to prevent and treat IHD, the development of new interventions for IHD and the re-use of statins for other androgen related conditions. Genetic confirmation that anakinra raises testosterone suggests its use in rheumatoid arthritis might have cardiovascular side-effects, particularly in men. It also highlights the importance of considering whether vulnerability to major diseases and interventions to promote lifespan need to be sex-specific.

## **Acknowledgement**

**Funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Conflict of interest:** None declared.

**Contributorship:** CMS initially planned, conducted, and reported the work described in this article. JVZ, SLAY and GML reviewed the first draft and suggested important additions to the design and content. JVZ additionally reviewed and checked the analysis plan and all the results. All authors reviewed and approved the final version. CMS is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. CMS affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Table 1: Sex-specific Mendelian randomization estimates for effects of genetically predicted statin, PCSK9 inhibitor and ezetimibe use (in effect sizes of LDL-cholesterol) on testosterone (effect size) in men and women using the UK Biobank summary statistics.

	Therapy	# SNPs	Inverse variance weighted			Weighted Median			MR-Egger			
			beta	95%CI	P value	beta	95%CI	P value	beta	95%CI	P value	Intercept (p-value)
Men	Statin	1	-0.15	-0.23 to -0.06	0.001							
	Statin	6	-0.15	-0.23 to -0.07	0.0005							
	PCSK9 inhibitor	3	0.04	-0.11 to 0.18	0.63	0.07	-0.13 to 0.27	0.29	0.34	0.09 to 0.60	0.01	-0.01 (0.01)
	PCSK9 inhibitor	7	0.05	-0.05 to 0.15	0.29							
	ezetimibe	1	0.04	-0.15 to 0.23	0.68							
	ezetimibe	3	0.05	-0.12 to 0.22	0.55	0.03	-0.13 to 0.18	0.72	0.24	-0.52 to 1.0	0.54	-0.01 (0.52)
Women	Statin	1	0.04	-0.06 to 0.14	0.45							
	Statin	6	0.03	-0.07 to 0.13	0.52							
	PCSK9 inhibitor	3	0.01	-0.11 to 0.14	0.85	0.01	-0.13 to 0.15	0.91	0.09	-0.38 to 0.56	0.71	-0.003 (0.74)
	PCSK9 inhibitor	7	-0.004	-0.14 to 0.13	0.95							
	ezetimibe	1	0.18	-0.05 to 0.40	0.12							
	ezetimibe	3	0.12	-0.08 to 0.31	0.24							

One statin SNP is rs12916, and 6 statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account their correlations.

Three PCSK9 inhibitor SNPs are rs11206510, rs2149041 and rs7552841, and 7 PCSK9 inhibitor SNPs additionally included rs10888897, rs2479394, rs2479409 and, rs562556 taking into account all their correlations

One ezetimibe SNP is rs2073547 (proxied by rs10260606), and 3 ezetimibe SNPs additionally included rs7791240 and rs217386 taking into account all their correlations.

The unit of LDL-cholesterol is approximately 0.83mm/L. An effect size of testosterone is approximately, 0.23nmol/L in women [78] and 3.1 nmol/L in men [79].

Table 2: Mendelian randomization estimates for effects of genetically predicted statin use (effect sizes of LDL-cholesterol) and of testosterone (effect size) on IHD in men and women using the UK Biobank individual data.

	Exposure	# SNPs	Inverse variance weighted			Weighted Median			MR-Egger			
			OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	Intercept (p-value)
Men	Statin use	1	0.55	0.38 to 0.79	0.001							
	Statin use	6	0.54	0.33 to 0.89	0.02							
	Testosterone	125	1.11	1.04 to 1.19	0.003	1.18	1.06 to 1.31	0.002	1.10	0.98 to 1.23	0.09	0.01 (0.84)
Women	Statin use	1	0.87	0.59 to 1.27	0.46							
	Statin use	6	0.79	0.54 to 1.13	0.20							
	Testosterone	254	0.96	0.89 to 1.03	0.29	1.03	0.92 to 1.14	0.63	1.08	0.94 to 1.23	0.27	-0.004 (0.05)

One statin SNP is rs12916, and 6 statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83mm/L. An effect size of testosterone is approximately, 0.23nmol/L in women [78] and 3.1 nmol/L in men [79].

Table 3: Multivariable Mendelian randomization estimates for effects of genetically predicted statin use (effect sizes of LDL-cholesterol) and of testosterone (effect size) together on IHD in men and women.

Exposure	Instrumented by	Adjusted for	Inverse variance weighted			MR-Egger				
			OR	95%CI	P value	OR	95% CI	p-value	Intercept p-value	
Men	Statin use	1 Statin SNP on LDL-cholesterol	Testosterone	1.05	0.74 to 1.47	0.79	0.73	0.48 to 1.11	0.14	
	Testosterone	125 SNPs on testosterone	statin SNPs	1.11	1.04 to 1.20	0.003	1.09	1.02 to 1.17	0.02	0.005
	Statin use	6 Statin SNPs on LDL-cholesterol	Testosterone	1.02	0.72 to 1.43	0.91				
	Testosterone	125 SNPs on testosterone	statin SNPs	1.11	1.04 to 1.20	0.003				
Women	Statin use	1 Statin SNP on LDL-cholesterol	Testosterone	0.98	0.75 to 1.16	0.53	0.72	0.55 to 0.94	0.02	
	Testosterone	254 SNPs on testosterone	statin SNPs	0.96	0.90 to 1.04	0.33	0.96	0.89 to 1.03	0.27	0.001
	Statin use	6 Statin SNPs on LDL-cholesterol	Testosterone	0.92	0.74 to 1.16	0.49				
	Testosterone	254 SNPs on testosterone	statin SNPs	0.97	0.90 to 1.04	0.36				

One statin SNP is rs12916, and 6 statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83mm/L. An effect size of testosterone is approximately, 0.23nmol/L in women [78] and 3.1 nmol/L in men [79]

Table 4: Mendelian randomization inverse variance weighted estimates for genetic effects of use of the anti-inflammatory anakinra raising IL-1Ra (effect size) [21] on testosterone (effect size) and ischemic heart disease and for genetic effects of use of tocilizumab raising IL-6 (log(pg/ml)) and IL-6R [22] on testosterone in men and women using the UK Biobank individual data.

	Therapy	target	outcome	# SNPs	measure	estimate	95% CI	p-value
Men	Anakinra	IL-1Ra	testosterone	2	beta	0.022	0.01 to 0.04	0.002
			IHD	2	OR	1.08	1.01 to 1.15	0.017
	Tocilizumab	IL-6	testosterone	1	beta	0.01	-0.04 to 0.06	0.66
			IHD	1	OR	0.99	0.91 to 1.08	0.86
Women	Anakinra	IL-1Ra	testosterone	2	beta	-0.01	-0.04 to 0.01	0.24
			IHD	2	OR	0.99	0.91 to 1.08	0.86
	Tocilizumab	IL-6	testosterone	1	beta	0.008	-0.07 to 0.09	0.84
			IHD	1	OR	0.99	0.91 to 1.08	0.86

SNPs for anakinra use are rs6743376 and rs1542176

SNP for tocilizumab use is rs7529229

An effect size of testosterone is approximately, 0.23nmol/L in women [78] and 3.1 nmol/L in men [79]




Figure 1: Directed acyclic graph showing the well-established protective effects of lipid modifiers and anti-inflammatories on IHD (solid lines) and possible additional pathways (dashed lines) investigated here. Green indicates a lowering effect, red indicates an increasing effect.




Figure 2: Schematic diagram showing the well-established protective effects of lipid modifiers on IHD (solid green lines) in the context of additional relevant pathways (green protective, red harmful) from an evolutionary biology perspective.

Key: GnRH: gonadotropin releasing hormone, RBC: red blood cell, LDL: low density lipoprotein

## References:

1. Ray KK, Corral P, Morales E, Nicholls SJ: **Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options.** *Lancet (London, England)* 2019, **394**(10199):697-708.
2. Michos ED, McEvoy JW, Blumenthal RS: **Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease.** *The New England journal of medicine* 2019, **381**(16):1557-1567.
3. Schonbeck U, Libby P: **Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?** *Circulation* 2004, **109**(21 Suppl 1):li18-26.
4. Aday AW, Ridker PM: **Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond.** *Frontiers in cardiovascular medicine* 2018, **5**:62.
5. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP: **PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.** *The Cochrane database of systematic reviews* 2017, **4**:Cd011748.
6. Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R: **A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.** *European journal of preventive cardiology* 2018, **25**(8):844-853.
7. Hobbs FD, Banach M, Mikhailidis DP, Malhotra A, Capewell S: **Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate.** *BMC medicine* 2016, **14**:4.
8. Schooling CM, Zhao JV: **How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?** *Am J Cardiovasc Drugs* 2019, **19**(2):107-111.
9. Sliz E, Kettunen J, Holmes MV, Williams CO, Boachie C, Wang Q, Mannikko M, Sebert S, Walters R, Lin K et al: **Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.** *Circulation* 2018, **138**(22):2499-2512.
10. Wurtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, Tiainen M, Perola M, Tillin T, Hughes AD et al: **Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase.** *J Am Coll Cardiol* 2016, **67**(10):1200-1210.
11. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ: **The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials.** *BMC medicine* 2013, **11**:57.
12. Plakogiannis R, Arif SA: **Women Versus Men: Is There Equal Benefit and Safety from Statins?** *Current atherosclerosis reports* 2016, **18**(2):6.
13. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H et al: **Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.** *Lancet (London, England)* 2015, **385**(9976):1397-1405.
14. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA: **Contributions of risk factors and medical care to cardiovascular mortality trends.** *Nat Rev Cardiol* 2015, **12**(9):508-530.
15. Smith GD, Ebrahim S: **'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?** *International journal of epidemiology* 2003, **32**(1):1-22.
16. Schooling CM, Lopez PM, Au Yeung SL, Huang JV: **Bias from competing risk before recruitment in Mendelian Randomization studies of conditions with shared etiology.** <https://www.biorxiv.org/content/101101/716621v2> 2019.
17. Schooling CM: **Biases in GWAS - the dog that did not bark.** <https://www.biorxiv.org/content/101101/709063v1> 2019.
18. Kesteloot H, Decramer M: **Age at death from different diseases: the flemish experience during the period 2000-2004.** *Acta Clin Belg* 2008, **63**(4):256-261.
19. Collins R: **What makes UK Biobank special?** *Lancet (London, England)* 2012, **379**(9822):1173-1174.
20. Ebrahimi F, Urwyler SA, Straumann S, Doerpfeld S, Bernasconi L, Neyer P, Schuetz P, Mueller B, Donath MY, Christ-Crain M: **IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial.** *The Journal of clinical endocrinology and metabolism* 2018, **103**(9):3466-3476.
21. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R et al: **The interleukin-6 receptor as a target for prevention of coronary heart disease: a**

- mendelian randomisation analysis.** *Lancet* 2012, **379**(9822):1214-1224.
22. **Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.** *Lancet Diabetes Endocrinol* 2015, **3**(4):243-253.
  23. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E *et al*: **Mendelian Randomization Study of ACLY and Cardiovascular Disease.** *The New England journal of medicine* 2019, **380**(11):1033-1042.
  24. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, Beaumont RN, Wittemans L, Martin S, Busch AS *et al*: **Using human genetics to understand the disease impacts of testosterone in men and women.** *Nat Med* 2020, **26**(2):252-258.
  25. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars NJ, Aguirre M, Venkataraman GR, Wainberg M, Ollila HN, Pirruccello JP, Qian J *et al*: **Genetics of 38 blood and urine biomarkers in the UK Biobank.** <https://www.biorxiv.org/content/10.1101/660506v1> 2019.
  26. Zhao JV, Schooling CM: **The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank.** *BMC Medicine* 2020, In press.
  27. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR: **Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic.** *International Journal of Epidemiology* 2016, **45**(6):1961-1974.
  28. Burgess S, Butterworth A, Thompson SG: **Mendelian randomization analysis with multiple genetic variants using summarized data.** *Genet Epidemiol* 2013, **37**(7):658-665.
  29. Sanderson E, Windmeijer F: **A weak instrument [Formula: see text]-test in linear IV models with multiple endogenous variables.** *J Econom* 2016, **190**(2):212-221.
  30. Sanderson E, Davey Smith G, Windmeijer F, Bowden J: **An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings.** *International journal of epidemiology* 2019, **48**(3):713-727.
  31. Bowden J, Davey Smith G, Burgess S: **Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.** *Int J Epidemiol* 2015, **44**(2):512-525.
  32. Bowden J, Davey Smith G, Haycock PC, Burgess S: **Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.** *Genet Epidemiol* 2016, **40**(4):304-314.
  33. Burgess S, Thompson SG: **Interpreting findings from Mendelian randomization using the MR-Egger method.** *European journal of epidemiology* 2017.
  34. Schooling CM, Au Yeung SL, Leung GM: **Why do statins reduce cardiovascular disease more than other lipid modulating therapies?** *Eur J Clin Invest* 2014, **44**(11):1135-1140.
  35. Schooling CM, Luo S, Au Yeung SL, Thompson DJ, Karthikeyan S, Bolton TR, Mason AM, Ingelsson E, Burgess S: **Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: a Mendelian randomization investigation.** *International journal of cardiology* 2018.
  36. Luo S, Au Yeung SL, Zhao JV, Burgess S, Schooling CM: **Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank.** *Bmj* 2019, **364**:l476.
  37. Mohammadi-Shemirani PC, M.; Pigeyre, M.; Morton, R.W.; Gerstein, H. G.; Pare, G.: **Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis.** *medRxiv* 2019, <https://www.medrxiv.org/content/10.1101/19005132v1>.
  38. Ooi TC, Raymond A, Cousins M, Favreau C, Taljaard M, Gavin C, Jolly EE, Malone S, Eapen L, Chretien M *et al*: **Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans.** *Clin Chim Acta* 2015, **446**:97-104.
  39. Krysiak R, Kowalska B, Zmuda W, Okopien B: **The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels.** *Pharmacol Rep* 2015, **67**(2):305-309.
  40. Shimizu-Albergine M, Van Yserloo B, Golkowski MG, Ong SE, Beavo JA, Bornfeldt KE: **SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP.** *Proceedings of the National Academy of Sciences of the United States of America* 2016, **113**(38):E5685-5693.
  41. Farnsworth WH, Hoeg JM, Maher M, Brittain EH, Sherins RJ, Brewer HB, Jr.: **Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.** *The Journal of clinical endocrinology and metabolism* 1987, **65**(3):546-550.

42. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL: **Preclinical evaluation of lovastatin**. *Am J Cardiol* 1988, **62**(15):16j-27j.
43. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S: **Androgen replacement therapy in male patients with rheumatoid arthritis**. *Arthritis Rheum* 1991, **34**(1):1-5.
44. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC: **Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews**. *Lancet Diabetes Endocrinol* 2016, **4**(11):943-956.
45. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA: **Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline**. *The Journal of clinical endocrinology and metabolism* 2018, **103**(5):1715-1744.
46. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK: **Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials**. *Jama* 2011, **306**(21):2359-2366.
47. Schooling CM: **Could androgens be relevant to partly explain why men have lower life expectancy than women?** *J Epidemiol Community Health* 2016, **70**(4):324-328.
48. Schooling CM, Ng JCM: **Reproduction and longevity: A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease**. *SSM Popul Health* 2019, **8**:100411.
49. Zhao JV, Luo S, Schooling CM: **Sex-specific Mendelian randomization study of genetically predicted insulin and cardiovascular events in the UK Biobank**. *Commun Biol* 2019, **2**:332.
50. Tran DQ, Ramos EH, Belsham DD: **Induction of GnRH mRNA expression by the omega-3 polyunsaturated fatty acid docosahexaenoic acid and the saturated fatty acid palmitate in a GnRH-synthesizing neuronal cell model, mHypoA-GnRH/GFP**. *Molecular and cellular endocrinology* 2016, **426**:125-135.
51. Matsuyama S, Kimura K: **Regulation of gonadotropin secretion by monitoring energy availability**. *Reprod Med Biol* 2015, **14**(2):39-47.
52. Kalra PS, Edwards TG, Xu B, Jain M, Kalra SP: **The anti-gonadotropic effects of cytokines: the role of neuropeptides**. *Domest Anim Endocrinol* 1998, **15**(5):321-332.
53. Tremellen K, McPhee N, Pearce K, Benson S, Schedlowski M, Engler H: **Endotoxin-initiated inflammation reduces testosterone production in men of reproductive age**. *Am J Physiol Endocrinol Metab* 2018, **314**(3):E206-e213.
54. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS *et al*: **Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction**. *The New England journal of medicine* 2019.
55. Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F: **Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2**. *Circulation* 2012, **126**(1):92-103.
56. Ajayi AA, Halushka PV: **Castration reduces platelet thromboxane A2 receptor density and aggregability**. *QJM : monthly journal of the Association of Physicians* 2005, **98**(5):349-356.
57. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ: **Influence of sex hormones on plasma endothelin levels**. *Ann Intern Med* 1993, **118**(6):429-432.
58. van Kesteren PJ, Kooistra T, Lansink M, van Kamp GJ, Asscheman H, Gooren LJ, Emeis JJ, Vischer UM, Stehouwer CD: **The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning**. *Thrombosis and haemostasis* 1998, **79**(5):1029-1033.
59. Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, Ray KK, Blaha MJ, Rysz J, Toth PP *et al*: **Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials**. *Atherosclerosis* 2015, **241**(2):433-442.
60. Rosselli M, Keller PJ, Dubey RK: **Role of nitric oxide in the biology, physiology and pathophysiology of reproduction**. *Hum Reprod Update* 1998, **4**(1):3-24.
61. Orsi FA, Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, van Hylckama Vlieg A, Bos MHA, Leebeek FWG, Cannegieter SC, Lijfering WM: **Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial**. *Journal of thrombosis and haemostasis : JTH* 2019, **17**(2):319-328.
62. Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA: **Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system**. *American journal of hematology* 1995, **49**(4):282-288.

63. Schooling CM, Kodali H, Li S, Borrell LN: **ET (Endothelin)-1 and Ischemic Heart Disease: A Mendelian Randomization Study.** *Circ Genom Precis Med* 2018, **11**(3):e002026.
64. Zhao JV, Schooling CM: **Coagulation Factors and the Risk of Ischemic Heart Disease, a Mendelian Randomization Study.** *Circ Genom Precis Med* 2018.
65. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC *et al*: **A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.** *Nature genetics* 2015, **47**(10):1121-1130.
66. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, Bittner V, Ray K, Watts GF, Hovingh GK *et al*: **The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.** *Thrombosis and haemostasis* 2016, **115**(3):520-532.
67. Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GY, Kees Hovingh G, Kastelein JJ, Kalinowski L, Rysz J *et al*: **A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.** *Scientific reports* 2015, **5**:9902.
68. Au Yeung SL, Lin SL, Lam HS, Schooling CM: **Effect of L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study.** *American heart journal* 2016, **182**:54-61.
69. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT *et al*: **Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.** *J Clin Endocrinol Metab* 2010, **95**(6):2560-2575.
70. Kanas T, Sinchar D, Osei-Hwedieh D, Baust JJ, Jordan A, Zimring JC, Waterman HR, de Wolski KS, Acker JP, Gladwin MT: **Testosterone-dependent sex differences in red blood cell hemolysis in storage, stress, and disease.** *Transfusion* 2016, **56**(10):2571-2583.
71. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F, Kostadima MA *et al*: **The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.** *Cell* 2016, **167**(5):1415-1429.e1419.
72. Schooling CM: **Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?** *Lancet (London, England)* 2017.
73. Burgess S, Davies NM, Thompson SG: **Bias due to participant overlap in two-sample Mendelian randomization.** *Genetic epidemiology* 2016, **40**(7):597-608.
74. Lopez PM, Subramanian SV, Schooling CM: **Effect measure modification conceptualized using selection diagrams as mediation by mechanisms of varying population-level relevance.** *J Clin Epidemiol* 2019, **113**:123-128.
75. Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, Holmes MV: **Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.** *PLoS Med* 2020, **17**(3):e1003062.
76. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D *et al*: **Interpretation of the evidence for the efficacy and safety of statin therapy.** *Lancet (London, England)* 2016, **388**(10059):2532-2561.
77. Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ: **The current evidence on statin use and prostate cancer prevention: are we there yet?** *Nat Rev Urol* 2017, **14**(2):107-119.
78. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G: **Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry.** *The Journal of clinical endocrinology and metabolism* 2012, **97**(2):408-415.
79. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB: **Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study.** *Clinical endocrinology* 2005, **62**(1):64-73.